Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Kiniksa Pharmaceuticals Ltd (KNSA)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Kiniksa Pharma's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
16.88 -0.07    -0.41%
18/04 - Closed. Currency in USD ( Disclaimer )
After Hours
16.88
0.00
0.00%
16:20:00 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 405,254
  • Bid/Ask: 16.75 / 17.91
  • Day's Range: 16.80 - 17.05
Kiniksa Pharma 16.88 -0.07 -0.41%

KNSA Recent Sentiments

 
This page contains information on users’ sentiments for the Kiniksa Pharmaceuticals Ltd stock, which are displayed both on charts of different periods of time and on a detailed table.
Start Date Username Call Open Rate End Date Chg. %
Jan 08, 2024 Aleene Brown   18.38 Feb 02, 2024 @ 18.38 0.00%
Jan 04, 2024 Sutrisno Adi   18.22 Jan 26, 2024 @ 18.22 0.00%
Dec 28, 2023 עמי וינברג   18.21 Jan 01, 2024 @ 17.54 -3.68%
Jul 25, 2023 Marco Zanetti   19.47 Jul 25, 2023 @ 19.25 +1.13%
Jul 25, 2023 Claudio Santoro   18.97 Nov 30, 2023 @ 15.82 -16.61%
Jul 14, 2023 Bas van der Meij   13.92 Nov 30, 2023 @ 15.82 +13.65%
Jun 26, 2023 aidan lambert   14.86 Nov 30, 2023 @ 15.82 +6.46%
Aug 24, 2022 احمد الغامدي   12.55 Aug 29, 2022 @ 11.86 -5.50%
Aug 04, 2022 IBRAHIM Alotibi   11.68 Aug 26, 2022 @ 12.22 +4.62%
Aug 03, 2022 Abdulaziz Alanazi   10.69 Aug 26, 2022 @ 12.22 +14.31%
Aug 03, 2022 Davide Carraro   11.03 Aug 26, 2022 @ 12.22 +10.79%
Dec 28, 2021 Freddy De Meersman   12.33 Jan 21, 2022 @ 10.37 -15.90%
Sep 14, 2021 Davide Carraro   12.04 Oct 08, 2021 @ 11.19 -7.06%
Jul 26, 2021 Davide Carraro   14.07 Aug 20, 2021 @ 12.20 -13.29%
Jul 01, 2021 Ashish Sheth   14.08 Jul 23, 2021 @ 14.50 -2.98%
Jul 01, 2021 Ashish Sheth   14.08 Jul 23, 2021 @ 14.50 +2.98%
Jun 21, 2021 Ling Tin Ko   14.38 Jun 21, 2021 @ 14.38 0.00%
Jun 08, 2021 Davide Carraro   13.88 Jul 02, 2021 @ 14.08 +1.44%
Apr 15, 2021 Aigerim Adilbekova   16.35 May 07, 2021 @ 14.63 -10.52%
Apr 15, 2021 Hizami Aziz   16.71 Apr 19, 2021 @ 15.15 -9.34%
Mar 23, 2021 Monika Moeun   18.73 Apr 16, 2021 @ 15.63 -16.55%
Mar 22, 2021 Monika Moeun   19.20 Mar 23, 2021 @ 18.73 +2.45%
Mar 19, 2021 Ben Crooke   20.69 Mar 20, 2021 @ 20.14 -2.66%
Mar 17, 2021 Nicholas Teo   22.32 Apr 09, 2021 @ 17.69 -20.74%
Mar 15, 2021 eugene emory   23.45 Apr 09, 2021 @ 17.69 -24.56%
Mar 09, 2021 Oscar Gigs   22.46 Mar 15, 2021 @ 23.00 +2.40%
Feb 22, 2021 Ashish Sheth   24.25 Mar 19, 2021 @ 20.14 -16.95%
Feb 22, 2021 Ashish Sheth   24.25 Mar 19, 2021 @ 20.14 -16.95%
Sep 15, 2020 Heino Entzeroth   17.64 Oct 09, 2020 @ 20.95 +18.76%
Aug 27, 2020 Jose Gomez Rial   16.25 Sep 18, 2020 @ 17.24 +6.09%
Jul 27, 2020 Aryan sheth   20.20 Aug 21, 2020 @ 17.64 +12.67%
Jul 27, 2020 Jose Gomez Rial   20.32 Aug 08, 2020 @ 19.70 -3.05%
Jul 21, 2020 Yair Berdugo   21.89 Aug 14, 2020 @ 17.70 -19.14%
Jul 16, 2020 Jose Gomez Rial   21.99 Jul 27, 2020 @ 20.32 +7.59%
Jul 09, 2020 Jose Gomez Rial   24.12 Jul 16, 2020 @ 21.99 -8.83%
May 21, 2020 Andreas Schatz   21.84 Jun 12, 2020 @ 21.52 -1.47%
May 13, 2020 G BHARATH SIMHA REDDY   19.75 Jun 05, 2020 @ 21.55 +9.11%
May 01, 2020 Jose Gomez Rial   19.16 May 22, 2020 @ 21.44 +11.90%
Apr 23, 2020 Andreas Schatz   20.56 May 15, 2020 @ 21.46 +4.38%
Apr 22, 2020 Cristián Villanueva   20.40 May 15, 2020 @ 21.46 +5.20%
Feb 04, 2020 Lorenzo Dagna   15.71 Feb 28, 2020 @ 18.46 +17.50%
Jan 09, 2020 Gabriel Gamboa   14.04 Jan 31, 2020 @ 14.71 +4.77%
Dec 10, 2019 mario shannon   14.50 Jan 03, 2020 @ 12.25 +15.52%
Nov 22, 2019 vbg99   8.94 Nov 25, 2019 @ 9.62 +7.61%
Nov 20, 2019 davide garulli   9.00 Dec 13, 2019 @ 12.57 -39.67%
Jul 09, 2019 Robbert Kuipers   15.79 Aug 02, 2019 @ 11.36 -28.06%
Dec 11, 2018 Fl Fa   24.64 Jan 10, 2019 @ 0.00 +100.00%
Dec 04, 2018 Angel Fernandez   20.77 Jan 03, 2019 @ 0.00 +100.00%
Nov 28, 2018 Nick_Sai   21.36 Dec 28, 2018 @ 0.00 -100.00%
Nov 21, 2018 Darren OConnor   20.55 Dec 21, 2018 @ 0.00 +100.00%
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

KNSA Comments

Write your thoughts about Kiniksa Pharmaceuticals Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Stephen Appiah
Stephen Appiah Mar 19, 2021 9:28AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I'm surprised no activity there is little activity on this stock.
Arl Nn
ArlN Mar 18, 2021 5:15PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The FDA has approved. - ARCALYST is the first and only FDA-approved therapy for recurrent pericarditis- Commercial launch expected in April 2021- Kiniksa launches Kiniksa One Connect™ patient support program
Arl Nn
ArlN Mar 15, 2021 6:26PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Breakthrough Therapy designation granted by the FDA for rilonacept for the treatment of recurrent pericarditis, due date is 21st March 2021 under priority review.That should help some movement
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email